Navigation Links
Cascade of Studies, New Clinical Tests Build the Case for Genetic Testing in Pharmacy Care Says Medco Expert
Date:2/26/2009

FRANKLIN LAKES, N.J., Feb. 26 /PRNewswire-FirstCall/ -- With more powerful, expensive and potentially dangerous medicines reaching the market on a daily basis, the time has come to leverage genetic tests that provide physicians with the confidence that they have prescribed the precise drug and dose tailored to their patient's unique genetic code, a leading authority on personalized medicine at Medco Health Solutions, Inc. (NYSE: MHS) today told industry leaders.

"We are at the precipice of a revolution in personalized medicine," said Felix Frueh, Medco vice president of personalized medicine research and development. "With greater frequency genetic testing is recommended in the medication label. Making such tests the standard of care can significantly reduce waste, improve patient care and raise the safety profile for powerful new medications."

Genetic tests associated with prescription medications represent an additional up-front cost in the early treatment of a condition. However, a building body of evidence is showing that genetic screenings can lead to greater savings over time from fewer hospital admissions and less waste, Frueh said. He predicts that the use of pharmacogenomic testing will become increasingly popular over the next several years as clinicians, patients and payors seek more opportunities to improve safety and efficacy in pharmacy care.

Pharmacogenomics is the science of capturing a patient's genetic information to help predict how a person is likely to respond to a wide variety of drugs, including commonly used medications such as pain relievers, blood thinners and cancer drugs. This information has a bearing on what drug is selected and may help optimize doses for particular drugs.

Addressing attendees of an audio conference hosted by magazine publisher Atlantic Inform
'/>"/>

SOURCE Medco Health Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. PartsSource wins Cascade Capital Technology Growth Award
2. Cascade Fresh Yogurt Announces Two Products to Optimize a Healthy Lifestyle
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers
5. In flurry of studies, researcher details role of apples in inhibiting breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Clinical depression linked to abnormal emotional brain circuits
8. Preclinical study suggests organ-transplant drug may aid in lupus fight
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Good Clinical Practice Journal Awards: Winners Announced
11. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...network of Hispanic health advocates committed to ..., WASHINGTON, Nov. 7 ... they have heard the voice of America,s families b...ct. Now the Senate must deliver, without delay, on...id Dr. Jane L. Delgado, President and CEO of the N...
(Date:11/8/2009)...assage of H.R. 3961 to Secure the Stability of Med...e/ -- Statement Attributable to: J. James Rohack, ..., (Logo: http://www.newscom.com/cgi-bin/prnh/20...e of the House health reform bill, which will help...ians and calls for swift passage of H.R. 3961 to s...
(Date:11/8/2009)...Shows Who Sides With Working Families vs. Insuranc...wire-USNewswire/ -- On the heels of an historic la...a good, balanced health care reform bill, the Penn...tate,s U.S. representatives voted on HR 3962, the ... legislation, which passed Saturday evening by a v...
(Date:11/7/2009)... Karen Ignagni, Preside...IP), released the following statement today on Hou...gly support comprehensive health care reform, and ...g a complete overhaul of how health insurance is p... coverage, elimination of pre-existing condition e...
(Date:11/7/2009)...RNewswire-USNewswire/ -- The American Medical Asso...or of Health at the Family Violence Prevention Fun...ay at its semi-annual policy-making meeting. The ...honor the AMA House of Delegates bestows on a non-...m/cgi-bin/prnh/20081209/AMALOGO ) ,, "Ms. Jam...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors Family Violence Prevention Expert 2
... on animal health has declared India as free from ...disease affecting the intestinal tract of cattle /...inderpest infection is a great achievement. It is ...ministry said in a statement Friday. 'This f...
...ader Sri Sri Ravishankar has said practising yoga,...away from drug and alcohol abuse. // 'Youths...to introduce yoga, pranayam and dhyan (meditation)...vi Shankar appealed to the youths to take up yoga ...
...rotests witnessed last month against the governmen...tions of higher education were a creation //of the...id here Friday 'The resistance (to the propo...ntral educational institutions, he said all politi...
... the research conducted by the U.S. Department of ...gues at Stony Brook University // , the IRCCS Neur...rsity it was found that improvements in the existi...ially tested on rats and the results of the study ...
...he Pentagon placed new restrictions on a doctors’...ere against any policy //that gives medical profe...ogaters’ to use harsher tactics than they would i... rights groups and medical ethicists. They charge ...
...government has cancelled examinations for recruitm... thereby providing more opportunities // to over 1...o low demand, we have cancelled all PLAB (Professi...t announced. Shiv Pande, Chairman of Indo-Bri...
Other Medicine News:Health News:India Declared Free of Rinderpest Cattle Infection 2Health News:Radiation Therapy Made More Compatible 2Health News:Radiation Therapy Made More Compatible 3Health News:Medical Role In Interrogations Curtailed By Pentagon 2
(Date:11/6/2009)...re-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA ), ...ducts for minimally disruptive surgical treatments... Michael J. Lambert as Executive Vice President an...009. The Company also announced several other Exe...l be an excellent complement to the NuVasive famil...
(Date:11/6/2009)...re-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: ...velopment of small-molecule therapeutics for the t...y virus (HIV), today reported recent accomplishmen... nine months ended September 30, 2009. ,, (Log...ARDEALOGO ) ,, "Since our last quarterly update...
(Date:11/6/2009)...re/ -- NexBio Inc., in collaboration with scientis...on (CDC), St. Louis University, and the University...two articles in the peer-reviewed journal PLoS ONE... (Fludase ® ) may play a potentially importan...demic Influenza A(H1N1) and drug-resistant influen...
Breaking Medicine Technology:NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense 53923 1LCA Announces More Requests for Bids on Lung Cancer Research Programs Funded Through the Department of Defense 53923 2National Alliance for Hispanic Health Applauds Confirmation of Sonia Sotomayor as the Nations 111th Supreme Court Justice 53920 1The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 1The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 2The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 3The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 4The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 5The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 6The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 7The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 8The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 9The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 10The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 11The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 12The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 13
...-(BUSINESS WIRE)--Mar 26, 2007 - A study comparing...nd hydralazine,(HYD) used in V-HeFT I and V-HeFT I...on, used in the African American Heart Failure,Tri...oequivalence,in the formulations used may explain ...esults in decreasing mortality. Using,identical am...
...atients already being treated with maximally,toler...her,reductions in LDL-C with similar reductions in...SIS 301012, NEW ORLEANS, and CARLSBAD, Calif., Mar...euticals, Inc. announced,results from its ongoing ...with homozygous familial hypercholesterolemia (HoF...
Other Medicine Technology:Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 2Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 3Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 4Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 5Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 2Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 3Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 4Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 5Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012,in Familial Hypercholesterolemia Patients Presented at ACC 6
E300 Corneal Topographer
...NPstream Genotyping System provides an automated s... over 800,000 SNP genotypes per day. Combined with...nd operational flexibility, this enables you to pr...st solution designed to deliver your intended resu...
...e upgrade including fourSight 4D ultrasound imagin...ystem offers a wide variety of imaging and workflo...atures that combine to expand the clinical capabil...ares system was built on four foundations that mar...
... laser-cut stent, is the latest in a succession of...y arteries have been opened with balloon catheters...oronary angioplasty (PTCA). The BeStent2 stent sys...optimize scaffolding, radiopacity and deliverabili...
Medicine Products: